In this special edition of DOC Updates, Neil Skolnik speaks with Dr. Juan Frias, who catalogues the latest cardiometabolic medications, emphasizing the distinguishing characteristics of each.<br>This special episode is sponsored with support from Lilly.<br>Presented by:<br>Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health<br>Juan Pablo Frias, MD, Medical Director and Principal Investigator, Los Angeles Institute for Metabolic Research, Adjunct Professor of Medicine at Charles Drew University of Medicine and Science

Special Edition: Medications in the Pipeline for Cardiometabolic Disease

DOC Updates

# Full Transcript

**Podcast:** DOC Updates

## Participants

- **Neil Skolnik** (Sidney Kimmel Medical College, Thomas Jefferson University; Abington Jefferson Health)
- **Juan Pablo Frias** (Los Angeles Institute for Metabolic Research)

## Transcript

Welcome to this special edition of DOC Updates, where we are going to discuss today an incredibly exciting topic, and that is medications in the cardiometabolic pipeline. That is medicines in the pipeline now for obesity, for diabetes, and for other cardiometabolic-related diseases.

This is an area that has truly become hard to keep up with, and it is more exciting than it ever has been, and it lets us from a practical point of view begin to understand the many ways that our abilities to help patients will continue to grow.

I'm Dr. Neil Skolnik, Professor of Family and Community Medicine at the Sidney Kimmel Medical College of Thomas Jefferson University, and this special edition of Diabetes Core Update is sponsored by Lilly. Joining us to discuss medicines in the pipeline, we are really privileged to have Dr. Juan Frias.

Dr. Juan Frias is the medical director and principal investigator at the Los Angeles Institute for Metabolic Research. He's been involved in diabetes, obesity, metabolic liver disease, and other metabolic-related research for over 25 years now, and has really authored an incredible number of studies, including being first author on the SURPASS-2 trial in the New England Journal of Medicine,

the phase 2 study of Orpher Gliperon in the Lancet, the phase 2 trial of CagriSema in the Lancet, other articles he's been authored on in the New England Journal of Medicine, Lancet, Lancet Diabetes and Endocrinology Diabetes, Diabetes Care Cell Metabolism. I could keep going, but I won't because we want to make sure we have time to discuss our topic today. You get it.

If you read the obesity and diabetes literature, you have seen his name a lot. Juan, welcome back to our podcast. It's such a pleasure to have seen you last week at the ADA Scientific Sessions and to be doing this podcast. No, absolutely. My pleasure. I really appreciate you having me back, and great to see you also last week, Neil. Juan, you've been in this field for a long time. Before I dive into the information, can you share with our audience just how you got interested in clinical research?

Yeah, no, absolutely. I think like so many other things, it's people you meet, mentors you have over time. I mean, I can remember even going back to medical school at Vanderbilt, you know, a million years ago or 40 years ago or whatever it was. My mentor there was an endocrinologist during my residency as well, an endocrinologist. So I just had a lot of people around me that were interested in metabolic disease and endocrinology. And then I was very fortunate to go to UCSD.

My mentor there was Jerry Alefsky, who's a big researcher. And I started with clinical research in my fellowship and have continued it now for over 30 years....

Special Edition: Medications in the Pipeline for Cardiometabolic Disease

Transcript

Built for investment professionals

Every day you wait, your competitors are finding
edge in conversations you're not hearing.

Special Edition: Medications in the Pipeline for Cardiometabolic Disease

Transcript

Built for investment professionals

Every day you wait, your competitors are findingedge in conversations you're not hearing.

Every day you wait, your competitors are finding
edge in conversations you're not hearing.